Characteristics of Newly Diagnosed COPD Patients Treated with Triple Inhaled Therapy by General Practitioners: a Real World Italian Study

Overview

Journal NPJ Prim Care Respir Med

Specialties Public Health
Pulmonary Medicine

Date 2017 Sep 9

PMID 28883469

Citations 11

Authors

Fabiano Di Marco

Pierachille Santus

Silvia Terraneo

Elena Peruzzi

Elisa Muscianisi

Claudio Ripellino

Valeria Pegoraro

Affiliations

Soon will be listed here.

Abstract

Chronic Lung Disease: ENSURING CORRECT PRESCRIPTIONS FOR EARLY-STAGE DISEASE: An improved education program for doctors promoting correct use of medication for chronic lung disease is needed in Italy. Current guidelines state that inhaled corticosteroids (ICSs) should be reserved for patients with severe chronic obstructive pulmonary disease (COPD), but it appears that doctors do not always follow this advice. Fabiano Di Marco, at San Paolo Hospital-Università degli Studi di Milano, and co-workers analyzed data from 32,046 COPD patients newly-diagnosed by family doctors in Italy between 2010 and 2013. When the researchers followed up on patients after 1 year, 2028 (6.3%) of newly-diagnosed patients were being treated with triple inhaled therapy incorporating ICSs-42% of these patients had started triple therapy immediately upon diagnosis. Being an older male and having been prescribed with a ICS/LABA FDC at diagnosis were strong predictors of triple therapy use within 1 year from the diagnosis.

Citing Articles

Clinical characteristics, use and switch of drugs for obstructive airway diseases among patients with COPD experiencing an exacerbation: a retrospective analysis of Italian administrative healthcare data.

Dondi L, Ronconi G, Calabria S, DellAnno I, Dondi L, Piccinni C BMC Pulm Med. 2024; 24(1):525.

PMID: 39438812 PMC: 11494943. DOI: 10.1186/s12890-024-03339-5.

Description and management of patients with anal fissure: insights on Italian primary care setting coming from real-world data.

Gallo G, Pegoraro V, Trompetto M Updates Surg. 2024; 76(6):2193-2203.

PMID: 38796820 PMC: 11541248. DOI: 10.1007/s13304-024-01882-8.

Acute treatment of migraine: quantifying the unmet need through real-world data in Italy.

Sacco S, Di Ciaccio S, Di Virgilio R, Pegoraro V, Ornello R Neurol Sci. 2024; 45(9):4427-4435.

PMID: 38538924 PMC: 11306385. DOI: 10.1007/s10072-024-07493-w.

Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities.

Matera M, Hanania N, Maniscalco M, Cazzola M Drugs Aging. 2023; 40(7):605-619.

PMID: 37316689 PMC: 10300166. DOI: 10.1007/s40266-023-01038-0.

Beyond Dual Bronchodilation - Triple Therapy, When and Why.

Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera M Int J Chron Obstruct Pulmon Dis. 2022; 17:165-180.

PMID: 35068929 PMC: 8766250. DOI: 10.2147/COPD.S345263.

References

Taylor A, Price K, Gill T, Adams R, Pilkington R, Carrangis N . Multimorbidity - not just an older person's issue. Results from an Australian biomedical study. BMC Public Health. 2010; 10:718. PMC: 3001730. DOI: 10.1186/1471-2458-10-718. View

Avanzini F, Marzona I, Baviera M, Barlera S, Milani V, Caimi V . Improving cardiovascular prevention in general practice: Results of a comprehensive personalized strategy in subjects at high risk. Eur J Prev Cardiol. 2015; 23(9):947-55. DOI: 10.1177/2047487315613664. View

Wurst K, Punekar Y, Shukla A . Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014; 9(9):e105296. PMC: 4152013. DOI: 10.1371/journal.pone.0105296. View

Osthoff M, Jenkins C, Leuppi J . Chronic obstructive pulmonary disease--a treatable disease. Swiss Med Wkly. 2013; 143:w13777. DOI: 10.4414/smw.2013.13777. View

Montuschi P, Ciabattoni G . Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015; 58(10):4131-64. DOI: 10.1021/jm5013227. View

Lehnert T, Heider D, Leicht H, Heinrich S, Corrieri S, Luppa M . Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011; 68(4):387-420. DOI: 10.1177/1077558711399580. View

Montuschi P, Malerba M, Macis G, Mores N, Santini G . Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov Today. 2016; 21(11):1820-1827. DOI: 10.1016/j.drudis.2016.07.009. View

Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi J . General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. 2010; 140. DOI: 10.4414/smw.2010.13053. View

Schwab P, Dhamane A, Hopson S, Moretz C, Annavarapu S, Burslem K . Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017; 12:735-744. PMC: 5327909. DOI: 10.2147/COPD.S112256. View

10.

Jones P, Willits L, Burge P, Calverley P . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003; 21(1):68-73. DOI: 10.1183/09031936.03.00013303. View

11.

Barnett K, Mercer S, Norbury M, Watt G, Wyke S, Guthrie B . Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380(9836):37-43. DOI: 10.1016/S0140-6736(12)60240-2. View

12.

Fumagalli G, Fabiani F, Forte S, Napolitano M, Balzano G, Bonini M . INDACO project: COPD and link between comorbidities, lung function and inhalation therapy. Multidiscip Respir Med. 2015; 10(1):4. PMC: 4429936. DOI: 10.1186/2049-6958-10-4. View

13.

Mahler D, Wire P, Horstman D, Chang C, Yates J, Fischer T . Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(8):1084-91. DOI: 10.1164/rccm.2112055. View

14.

Suissa S, Barnes P . Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009; 34(1):13-6. DOI: 10.1183/09031936.00190908. View

15.

Wedzicha J, Banerji D, Chapman K, Vestbo J, Roche N, Ayers R . Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016; 374(23):2222-34. DOI: 10.1056/NEJMoa1516385. View

16.

Cazzola M, Molimard M . The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010; 23(4):257-67. DOI: 10.1016/j.pupt.2010.03.003. View

17.

Donaldson G, Seemungal T, Bhowmik A, Wedzicha J . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57(10):847-52. PMC: 1746193. DOI: 10.1136/thorax.57.10.847. View

18.

Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer S . Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015; 350:h949. PMC: 4356453. DOI: 10.1136/bmj.h949. View

19.

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356):449-56. DOI: 10.1016/S0140-6736(03)12459-2. View

20.

Bettoncelli G, Blasi F, Brusasco V, Centanni S, Corrado A, De Benedetto F . The clinical and integrated management of COPD. An official document of AIMAR (Interdisciplinary Association for Research in Lung Disease), AIPO (Italian Association of Hospital Pulmonologists), SIMER (Italian Society of Respiratory Medicine), SIMG.... Multidiscip Respir Med. 2014; 9(1):25. PMC: 4107539. DOI: 10.1186/2049-6958-9-25. View